Arizona State Retirement System Purchases New Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Arizona State Retirement System acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 30,174 shares of the company’s stock, valued at approximately $183,000.

A number of other institutional investors have also recently bought and sold shares of AMRX. Gladius Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $39,000. Sherbrooke Park Advisers LLC bought a new stake in Amneal Pharmaceuticals during the third quarter worth about $54,000. Aigen Investment Management LP acquired a new stake in Amneal Pharmaceuticals during the third quarter worth about $118,000. Public Employees Retirement System of Ohio bought a new position in Amneal Pharmaceuticals in the 3rd quarter valued at about $160,000. Finally, EMC Capital Management raised its position in shares of Amneal Pharmaceuticals by 886.7% in the 3rd quarter. EMC Capital Management now owns 40,613 shares of the company’s stock valued at $171,000 after buying an additional 36,497 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AMRX shares. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. The Goldman Sachs Group lifted their price target on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research note on Monday, March 4th. Piper Sandler upped their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Finally, StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $7.31.

Amneal Pharmaceuticals Stock Down 0.9 %

Shares of AMRX opened at $5.37 on Tuesday. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -17.32 and a beta of 1.33. Amneal Pharmaceuticals, Inc. has a 52 week low of $1.58 and a 52 week high of $6.46. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.94 and a current ratio of 1.63. The stock has a fifty day moving average of $5.72 and a 200-day moving average of $5.16.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.07. The company had revenue of $616.98 million for the quarter, compared to analysts’ expectations of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.